Promising new treatments on the horizon MS Trust Daclizumab, also known as Zenepax, is a monoclonal antibody already licensed for prevention of kidney transplant rejection. The SELECT trial tested subcutaneous (under the skin) injections of either placebo or daclizumab in people with relapsing ... |
